Larimar Therapeutics (LRMR)
(Delayed Data from NSDQ)
$7.44 USD
+0.29 (4.06%)
Updated Aug 8, 2024 03:59 PM ET
After-Market: $7.44 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
D Value F Growth D Momentum F VGM
Cash flow Statements
Fiscal Year End for Larimar Therapeutics, Inc falls in the month of December.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | -36.95 | -35.36 | -50.64 | -42.48 | -45.41 |
Depreciation/Amortization & Depletion | -1.53 | -0.46 | 0.31 | 0.17 | -0.53 |
Net Change from Assets/Liabilities | -2.51 | 1.67 | 2.75 | -2.04 | -0.38 |
Net Cash from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Operating Activities | 7.53 | 6.57 | 5.47 | 2.16 | 5.53 |
Net Cash From Operating Activities | -33.46 | -27.57 | -42.11 | -42.20 | -40.78 |
Property & Equipment | -0.16 | -0.10 | -0.33 | -0.06 | -0.76 |
Acquisition/ Disposition of Subsidiaries | 0.00 | 0.00 | 0.00 | 41.93 | 0.00 |
Investments | 33.52 | -90.86 | 24.50 | -23.49 | 26.61 |
Other Investing Activities | 0.00 | 0.00 | 0.00 | -1.30 | -0.59 |
Net Cash from Investing Activities | 33.35 | -90.96 | 24.17 | 17.09 | 25.26 |
Uses of Funds
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | 0.03 | 75.26 | 19.89 | 75.59 | 0.19 |
Issuance (Repayment) of Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Increase (Decrease) Short-Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | -5.46 |
Payment of Dividends & Other Distributions | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Financing Activities | 0.00 | 0.00 | 0.00 | 18.00 | 0.00 |
Net Cash from Financing Activities | 0.03 | 75.26 | 19.89 | 93.59 | -5.26 |
Effect of Exchange Rate Changes | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Change In Cash & Equivalents | -0.08 | -43.27 | 1.95 | 68.48 | -20.78 |
Cash at Beginning of Period | 28.16 | 71.44 | 69.49 | 1.01 | 49.33 |
Cash at End of Period | 28.09 | 28.16 | 71.44 | 69.49 | 28.55 |
Diluted Net EPS | -0.84 | -1.37 | -2.95 | -3.57 | -14.65 |
Fiscal Year End for Larimar Therapeutics, Inc falls in the month of December.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | NA | -14.65 | -36.95 | -23.96 | -14.89 |
Depreciation/Amortization & Depletion | NA | -0.50 | -1.53 | -0.98 | -0.49 |
Net Change from Assets/Liabilities | NA | 2.66 | -2.51 | -4.82 | -3.36 |
Net Cash from Discontinued Operations | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Operating Activities | NA | 2.09 | 7.53 | 5.64 | 3.83 |
Net Cash From Operating Activities | NA | -10.41 | -33.46 | -24.12 | -14.92 |
Property & Equipment | NA | 0.00 | -0.16 | 0.00 | 0.00 |
Acquisition/ Disposition of Subsidiaries | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Investments | NA | -68.36 | 33.52 | 35.98 | 82.41 |
Other Investing Activities | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Net Cash from Investing Activities | NA | -68.36 | 33.35 | 35.98 | 82.41 |
Uses of Funds
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | NA | 162.15 | 0.03 | 0.03 | 0.00 |
Issuance (Repayment) of Debt | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Increase (Decrease) Short-Term Debt | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Payment of Dividends & Other Distributions | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Financing Activities | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Net Cash from Financing Activities | NA | 162.15 | 0.03 | 0.03 | 0.00 |
Effect of Exchange Rate Changes | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Net Change In Cash & Equivalents | NA | 83.38 | -0.08 | 11.90 | 67.50 |
Cash at Beginning of Period | NA | 28.09 | 28.16 | 28.16 | 28.16 |
Cash at End of Period | NA | 111.46 | 28.09 | 40.06 | 95.66 |
Diluted Net EPS | NA | -0.27 | -0.29 | -0.21 | -0.19 |